It has been reported that the incidence of all grades of ALT/AST elevation was 21–25% under sorafenib treatment with no fatal cases of hepatic failure, while the incidence was 45–65% for all grades and 6% for grade 3-4 in regorafenib administration and is sufficiently high and severe to acquire a boxed label warning56. Here, GPT is linked to liver failure.